Endometrioma (Palliative Investigational Adjunct)
Palliative investigational adjunct for endometrioma-related chronic pelvic pain in patients declining or unable to undergo surgical/hormonal management.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for endometrioma. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is Tier C investigational and palliative-only, with no disease-modifying mechanism.
- What evidence exists?
- Tier C (investigational). No controlled trials exist for hirudotherapy in endometrioma. Endometriomas are ovarian endometriotic cysts, a subtype of endometriosis, typically discovered on pelvic imaging. Evidence-based management includes hormonal suppression (combined oral contraceptives, progestins, GnRH agonists/antagonists, dienogest), laparoscopic cystectomy with biopsy (preferred over drainage for diagnosis and recurrence reduction), and addressing concurrent endometriosis. Premenopausal women considering surgery require AMH (anti-Mullerian hormone) assessment and discussion of impact on ovarian reserve.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Bruising and tenderness over the lower abdomen for 5 to 10 days
- Local skin infection or Aeromonas infection
- Allergic reaction to leech saliva
- Cannot reach or affect the deep ovarian cyst from topical placement
- Delay of hormonal suppression or laparoscopic cystectomy, both of which are evidence-based
- Missed malignant transformation (rare but reported in endometriomas)
- Missed infertility evaluation if pregnancy is desired
- Who should not consider this
- Pregnant patients
- Patients with suspected malignant transformation
- Patients with acute endometrioma rupture or torsion (surgical emergency)
- Patients in active infertility evaluation considering surgery
- Patients within 12 weeks of abdominal or pelvic surgery
- Patients on anticoagulants or with severe anemia
- What to ask your clinician
- Has endometrioma been confirmed by ultrasound or MRI, with malignancy concern addressed?
- Have I been offered hormonal suppression (combined OC, progestins, dienogest, GnRH agonist/antagonist)?
- Have I been offered laparoscopic cystectomy, and what does AMH testing show about my ovarian reserve?
- If I want to preserve fertility, have I been referred to reproductive endocrinology?
- Where exactly will the leech be placed, and why is the abdominal wall expected to help a deep ovarian cyst?
- Has it been clearly explained that this is palliative-only, not disease-modifying?
- When to seek urgent care
- Sudden severe one-sided abdominal or pelvic pain (rule out rupture or torsion)
- Heavy or unusual vaginal bleeding
- Fever above 38.0 C / 100.4 F or chills
- Persistent vomiting or signs of acute abdomen
- Bleeding from a bite site lasting more than 24 hours
- Spreading redness, warmth, or pus at any bite site
What this does NOT mean
- It does not shrink or treat endometriomas — the ovarian cyst is anatomically deep and inaccessible.
- It does not replace hormonal suppression or laparoscopic cystectomy, both of which have evidence support.
- It does not address infertility or improve fertility outcomes.
- It is palliative only and only when standard therapy is declined or unavailable.
Safety cross-references
Clinical Profile
- Category
- gynecologic
- ICD-10
- N80.1, N80.10
- Safety tier
- medium
Evidence Summary
Endometriomas are ovarian endometriotic cysts, a subtype of endometriosis, typically discovered on pelvic imaging. Evidence-based management includes hormonal suppression (combined oral contraceptives, progestins, GnRH agonists/antagonists, dienogest), laparoscopic cystectomy with biopsy (preserved over drainage for diagnosis and recurrence reduction), and addressing concurrent endometriosis. Premenopausal women considering surgery require AMH assessment and discussion of ovarian reserve impact. No published controlled trials of hirudotherapy exist for endometrioma. Lower abdominal placement is purely symptomatic-palliative, with no plausible disease-modifying mechanism; the deep pelvic location is inaccessible to topical agents.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Pregnancy
- Suspected malignant transformation (rare but reported)
- Acute endometrioma rupture or torsion
- Concurrent infertility evaluation actively considering surgery
- Recent abdominal surgery
Related Conditions
Lactational Mastitis (Non-Suppurative)
Investigational adjunctive use for non-suppurative lactational mastitis; case-series evidence for resolution of induration and reduced antibiotic days.
Endometriosis-Related Pelvic Pain
Investigational adjunctive use for chronic endometriosis-related pelvic pain; very limited evidence. Not a substitute for hormonal or surgical management.
Primary Dysmenorrhea
Investigational use for primary dysmenorrhea refractory to NSAIDs and hormonal contraception; small case series.
Chronic Pelvic Pain Syndrome (Non-Specific)
Investigational use for non-specific chronic pelvic pain syndrome; case-series evidence for symptom reduction within multimodal management.